Mergers & Acquisition - Companies working on Deuterated Drugs
Deuterated medication mergers and acquisitions (M&A) have been a major trend in the pharmaceutical sector in recent years. Some of the trends in Mergers & Acquisitions of companies working in deuterated drug discovery
Strategic Partnerships : Pharmaceutical companies are increasingly entering into partnerships or acquiring biotech firms specializing in deuterated drug development. This strategy allows them to access novel technologies and intellectual property related to deuteration.
Pipeline Expansion : Acquiring companies often seek to expand their drug pipelines with promising deuterated drug candidates. These candidates may offer differentiated therapeutic benefits over existing drugs or treat conditions where traditional formulations have limitations.
Market Potential : Deuterated drugs have the potential to address unmet medical needs or improve upon existing therapies. This market potential drives M&A activities as companies strive to capitalize on innovative treatments.
Technological Expertise : Companies involved in M&A transactions may gain access to specialized expertise in deuteration chemistry, formulation development, or preclinical and clinical research methodologies specific to deuterated drugs.
M&A Deuterated Drugs
Parent Company | Acquired by | Molecule | Therapeutic Indication | M&A Value |
---|---|---|---|---|
Auspex [2015] | Teva | Austedo (deutetrabenazine) | Huntington's disease | $ 3.5Bn |
Avanir [2014] | Otsuka Pharmaceutical | AVP-786 | Agitation in Alzheimer's disease | $ 3.5Bn |
Concert Pharmaceuticals [2021] | Vertex | CTP-656 VX-561 | Cystic fibrosis | $ 160Mn |
DeuteRx [2018] | Poxel | DRX-065 | NASH | $ 8Mn in cash/ $ 1.29Mn shares |
Vertex [2017] | Merck KGaA | M9831 | Anti-cancer drug | $ 230Mn |
Concert [2023] | Sun Pharma | Deuruxolitinib | Severe Alopecia Areata | $576Mn |